3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
377
Myelodysplastic Syndromes
159
Leukemia, Myelomonocytic, Chronic
76
Leukemia
65
Recurrence
32
Myeloproliferative Disorders
23
Hematologic Neoplasms
20
Neoplasms
19
Multiple Myeloma
17
Carcinoma, Non-Small-Cell Lung
17
Lymphoma, Non-Hodgkin
16
Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma, Large B-Cell, Diffuse
14
Anemia, Refractory, with Excess of Blasts
14
Lymphoma, T-Cell, Peripheral
13
Primary Myelofibrosis
12
Neoplasm, Residual
12
Leukemia, Monocytic, Acute
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Leukemia, Biphenotypic, Acute
11
Leukemia, Myelomonocytic, Acute
10
Hodgkin Disease
10
Myelodysplastic-Myeloproliferative Diseases
9
Leukemia, Erythroblastic, Acute
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myeloid
8
Leukemia, Megakaryoblastic, Acute
8
Congenital Abnormalities
8
Breast Neoplasms
8
Interventions
Temozolomide
156
Bevacizumab
69
Radiotherapy
61
Magnetic Resonance Spectroscopy
59
Irinotecan
31
Surgical Procedures, Operative
23
Radiation
23
Carboplatin
23
Specimen Handling
20
Carmustine
20
Nivolumab
19
Biopsy
17
Lomustine
16
Aminolevulinic Acid
15
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
trametinib
12
pembrolizumab
12
Radiosurgery
12
Erlotinib Hydrochloride
12
fluorodopa F 18
11
Topotecan
11
Everolimus
11
Blood Specimen Collection
11
X-Rays
10
IL13-PE38
10
dabrafenib
9
Etoposide
9
ribociclib
8
poly ICLC
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Glioma
×
Azacitidine
×
Clear all
NCT03666559
2024-02-29
AGIR
Assistance Publique - Hôpitaux de Paris
Phase 2
Unknown
8 enrolled